Table of Content

Chapter 1 Introduction
1.1 Study Goals and Objectives
1.2 Reasons for Doing this Study
1.3 What’s New in this Report
1.4 Scope of Report
1.5 Information Sources
1.6 Methodology
1.7 Geographic Breakdown
1.8 Analyst’s Credentials

Chapter 2 Summary and Highlights

Chapter 3 Market Overview
3.1 Introduction
3.1.1 Kidneys
3.1.2 Renal Biomarkers
3.1.3 Definition
3.2 Market Dynamics
3.2.1 Drivers
3.2.2 Restraints
3.2.3 Opportunities
3.3 Regulatory Process for Biomarkers
3.3.1 European Medicines Agency
3.3.2 Biomarkers Qualified by the FDA

Chapter 4 Impact of COVID-19 Pandemic
4.1 Impact of COVID-19 on Renal Biomarker Market
4.1.1 Increased Incidence of AKI
4.1.2 Other Diseases
4.2 Chronic Dialysis Patients
4.2.1 Kidney Transplant Recipients

Chapter 5 Global Renal Biomarker Market by Type
5.1 Overview
5.2 Filtered Renal Biomarkers (Impaired Tubular Reabsorption)
5.2.1 Albumin
5.2.2 Cystatin C
5.2.3 Beta-2 Microglobulin
5.3 Upregulated Biomarkers
5.3.1 KIM-1 Kidney Injury Molecule
5.3.2 Neutrophil Gelatinase Associated Lipocalin
5.3.3 Clusterin
5.3.4 Interleukin-18
5.3.5 Netrin-1
5.4 Preformed
5.4.1 Alkaline Phosphatase
5.4.2 Gamma-Glutamyl Transpeptidase
5.4.3 Glutathione S-Transferase
5.4.4 N-acetyl-?-D Glucosaminidase
5.4.5 Liver-Type Fatty Acid-Binding Protein
5.4.6 Tissue Inhibitor of Metalloprotease-2 and Insulin-Like Growth Factor-binding Protein 7
5.5 Other Biomarkers
5.5.1 Blood Urea Nitrogen
5.5.2 Serum Creatinine
5.5.3 Downregulated

Chapter 6 Global Market for Renal Biomarkers by Region
6.1 North America
6.1.1 United States
6.1.2 Canada
6.2 Europe
6.2.1 Germany
6.2.2 Italy
6.2.3 France
6.2.4 Spain
6.2.5 United Kingdom
6.2.6 Rest of Europe
6.3 Asia-Pacific
6.3.1 Australia
6.3.2 Japan
6.3.3 China
6.3.4 Rest of Asia
6.4 Rest of the World

Chapter 7 Renal Biomarker Market by End User
7.1 Hospitals
7.2 Research Centers
7.3 Other End Users

Chapter 8 Renal Biomarker Market by Technique
8.1 Overview
8.2 Enzyme Linked Immunosorbent Assay
8.3 Particle-Enhanced Turbidimetric Immunoassays
8.4 Colorimetric Assays
8.5 Chemiluminescent Enzyme Immunoassays
8.6 Other Detection Methods

Chapter 9 Competitive Landscape

Chapter 10 Company Profiles
ABBOTT LABORATORIES
BECKMAN COULTER INC.
BIOMERIEUX
BIOPORTO A/S
BIO-RAD
ENZO BIOCHEM INC.
GENTIAN DIAGNOSTIC AB
HYTEST LTD.
NEPHROSANT
Nexelis
PROTEOMICS INTERNATIONAL LABORATORIES LTD.
RANDOX LABORATORIES LTD.
ROCHE (F. HOFFMANN-LA ROCHE AG)
SPHINGOTEC
THERMO FISHER SCIENTIFIC

Chapter 11 Patent Review

Chapter 12 Clinical Trial Analysis



List of Figures


Summary Figure : Global Market for Renal Biomarkers, by Type, 2019-2027
Figure 1 : Applications for Biomarkers
Figure 2 : Timeline for Renal Biomarkers
Figure 3 : Initial Timeline of EMA Biomarker Qualification
Figure 4 : Flowchart of EMA Biomarker Qualification Process
Figure 5 : Steps in EMA Biomarker Qualification
Figure 6 : Steps in Biomarker Quantification
Figure 7 : Pathways for Excretion of IGFBP7 and TIMP-2
Figure 8 : Percentage of CKD Patients, by Age, in U.S.
Figure 9 : Number of Patients Receiving Kidney Dialysis in Canada
Figure 10 : EU Patients Undergoing Kidney Dialysis and Transplants
Figure 11 : Shares of Leading Companies in the Renal Biomarker Market
Figure 12 : Clinical Trials of Renal Biomarkers, by Therapeutic Area, 2019 to October 2022
Figure 13 : Clinical Trials of Renal Biomarkers, by Sponsor
Figure 14 : Clinical Trials of Renal Biomarkers, by Location

List of Tables


Summary Table : Global Market for Renal Biomarkers, by Segment, Through 2027
Table 1 : Applications for Biomarkers, with Examples
Table 2 : Changes in Aging Kidneys
Table 3 : Qualified Biomarkers of EMA SAWP/CHMP, as of March 30, 2020
Table 4 : Stages in the FDA Biomarker Qualification Program
Table 5 : Qualified Biomarkers for FDA CDER BQP, as of Feb. 19, 2020
Table 6 : Cases of COVID-19 and Related Deaths, by Country, as of October 2022
Table 7 : Effects of COVID-19 on Kidney Disease Patients
Table 8 : Properties of KIM-1
Table 9 : Global Market for Renal Biomarkers, by Region, Through 2027
Table 10 : AKI in Developed and Developing Countries
Table 11 : North American Market for Renal Biomarkers, by Country, Through 2027
Table 12 : North American Market for Renal Biomarkers, by Type, Through 2027
Table 13 : U.S. Market for Renal Biomarkers, by Type, Through 2027
Table 14 : Canadian Market for Renal Biomarkers, by Type, Through 2027
Table 15 : European Kidney Health Alliance Recommendations
Table 16 : European Market for Renal Biomarkers, by Region, Through 2027
Table 17 : European Market for Renal Biomarkers, by Type, Through 2027
Table 18 : German Market for Renal Biomarkers, by Type, Through 2027
Table 19 : Italian Market for Renal Biomarkers, by Type, Through 2027
Table 20 : French Market for Renal Biomarkers, by Type, Through 2027
Table 21 : Spanish Market for Renal Biomarkers, by Type, Through 2027
Table 22 : U.K. Market for Renal Biomarkers, by Type, Through 2027
Table 23 : Rest of Europe Market for Renal Biomarkers, by Type, Through 2027
Table 24 : Asia-Pacific Market for Renal Biomarkers, by Country, Through 2027
Table 25 : Asia-Pacific Market for Renal Biomarkers, by Type, Through 2027
Table 26 : Australian Market for Renal Biomarkers, by Type, Through 2027
Table 27 : Japanese Market for Renal Biomarkers, by Type, Through 2027
Table 28 : Chinese Market for Renal Biomarkers, by Type, Through 2027
Table 29 : Rest of Asia Market for Renal Biomarkers, by Type, Through 2027
Table 30 : RoW Market for Renal Biomarkers, by Type, Through 2027
Table 31 : Global Market for Renal Biomarkers, by End User, Through 2027
Table 32 : Global Market for Renal Biomarkers, by Technique, Through 2027
Table 33 : Methods for Detection of Renal Biomarkers
Table 34 : Company Developments, 2019-2022
Table 35 : Abbott Laboratories: Renal Biomarker Portfolio
Table 36 : Abbott Laboratories: Revenue and R&D Expenses, 2019 to 2021
Table 37 : Abbott Laboratories: Revenue, by Segment
Table 38 : BioMerieux: Revenue and R&D Expenditure, 2019-2021
Table 39 : BioMerieux: Revenue of Immunoassay Segment, 2019-2021
Table 40 : BioMerieux: Recent Developments, 2019-2022
Table 41 : Bioporto: Revenue and R&D Expense, 2019-2021
Table 42 : Bioporto: NGAL Revenue, 2019-2021
Table 43 : Bioporto: Recent Developments, 2019-2022
Table 44 : Bio-Rad: Kidney Toxicity Assay Portfolio
Table 45 : Bio-Rad: Revenue and R&D Expense, 2019-2021
Table 46 : Enzo Biochem: Revenue and R&D Expenses, 2019-2021
Table 47 : Enzo Biochem: Revenue, by Segment, 2019-2021
Table 48 : Enzo Biochem: Revenue, by Region, 2019 to 2021
Table 49 : Gentian Diagnostic: Revenue, by Region, 2019-2021
Table 50 : Gentian Diagnostic: Recent Developments, 2019-2022
Table 51 : Nexelis: Recent Developments, 2019-2022
Table 52 : Nexelis: Renal Biomarker Portfolio
Table 53 : Proteomics International: Revenue, 2019-2022
Table 54 : Proteomics: Recent Developments, 2019-2022
Table 55 : Roche: Revenue and R&D Expenses, 2019-2021
Table 56 : Roche: Revenue, by Segment, 2019-2021
Table 57 : Roche: Revenue, by Diagnostic Segment, 2019-2021
Table 58 : Roche: Revenue, by Region, 2019 to 2022
Table 59 : Sphingotec: Recent Developments, 2019-2022
Table 60 : Thermo Fisher Scientific: Revenue and R&D Expenses, 2019-2021
Table 61 : Thermo Fisher Scientific: Revenue, by Segment, 2019-2021
Table 62 : Thermo Fisher Scientific: Recent Developments, 2019-2022
Table 63 : Precision Medicine Patent Criteria in U.S. and Europe
Table 64 : List of Renal Biomarker Patents